1. Home
  2. RCKT vs AKBA Comparison

RCKT vs AKBA Comparison

Compare RCKT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

N/A

Current Price

$2.44

Market Cap

277.7M

Sector

Health Care

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.54

Market Cap

248.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RCKT
AKBA
Founded
1999
2007
Country
United States
United States
Employees
202
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
277.7M
248.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
RCKT
AKBA
Price
$2.44
$0.54
Analyst Decision
Buy
Buy
Analyst Count
14
6
Target Price
★ $8.58
$3.25
AVG Volume (30 Days)
1.8M
★ 9.5M
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
26.37
★ 93.94
EPS
★ 0.66
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$915.60
N/A
P/E Ratio
$3.75
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.17
$0.36
52 Week High
$5.45
$1.84

Technical Indicators

Market Signals
Indicator
RCKT
AKBA
Relative Strength Index (RSI) 46.44 39.44
Support Level $2.17 N/A
Resistance Level $2.73 $1.00
Average True Range (ATR) 0.19 0.08
MACD 0.04 -0.01
Stochastic Oscillator 53.98 40.47

Price Performance

Historical Comparison
RCKT
AKBA

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: